Screening for prostate cancer with prostate-specific antigen: beware the biases (Q34453090)

2 August 2017

0 references

Screening for prostate cancer with prostate-specific antigen: beware the biases (English)

1 reference

2 August 2017

1 reference

1 reference

Peter S. Bunting

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A11728412

31 January 2025

publication date

1 January 2002

1 reference

2 August 2017

January 2002

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=11728412

31 January 2025

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=11728412

31 January 2025

number of pages

27

1 reference

https://api.elsevier.com/content/article/PII:S0009898101007173?httpAccept=text/xml

inferred from page(s)

work available at URL

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

https://api.elsevier.com/content/article/PII:S0009898101007173?httpAccept=text/plain

31 January 2025

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

31 January 2025

1 reference

2 August 2017

volume

315

1 reference

2 August 2017

issue

1-2

1 reference

2 August 2017

page(s)

71-97

1 reference

publication type of scholarly work

2 August 2017

review article

1 reference

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diagnosis and management of early prostate cancer. Report of a British association of urological surgeons working party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

American Cancer Society guideline for the early detection of prostate cancer: update 1997

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening: a public health dilemma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Ethics of a prostate cancer screening trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate Cancer Screening in the Midst of Controversy: Canadian Men’s Knowledge, Beliefs, Utilization, and Future Intentions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Rationale for randomised trials of prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer of the prostate: A nutritional disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diet, androgens, oxidative stress and prostate cancer susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Family history facilitates the early diagnosis of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Familial prostate cancer: a different disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Age-specific reference ranges for serum prostate-specific antigen in black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Racial differences in operating characteristics of prostate cancer screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Correlation of pathologic findings with progression after radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer screening. Degrees of proof and practical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Appraising organised screening programmes for testing for genetic susceptibility to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening: promise and peril--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Are increasing 5-year survival rates evidence of success against cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Impact of prostate-specific antigen screening on the natural history of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Analysis of recent trends in prostate cancer incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Progress and problems in screening for carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Evaluation of annual examinations in the detection of cancer. Special reference to cancer of the gastrointestinal tract, prostate, breast, and female generative tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer: comparison of transrectal US and digital rectal examination for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A screening study of prostate cancer in high risk families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

An evaluation of serial digital rectal examinations in screening for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Accuracy of Digital Rectal Examination and Transrectal Ultrasonography in Localizing Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Is there still a role for prostatic acid phosphatase? CSCC Position Statement. Canadian Society of Clinical Chemists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The use of percent free prostate specific antigen for staging clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

An Evaluation of Prostate-Specific Antigen as a Screening Test for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection program for prostate cancer: results and identification of high-risk patient population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Etiology and diagnosis of prostate cancer: what's new? A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The new human kallikrein gene family: implications in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A guide to the interpretation of serum prostate specific antigen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Free and total prostate-specific antigen in a screened population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The stability of free and bound prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal screening for prostate cancer with prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer: an analysis of the early experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of pathologic characteristics of T1c and non-Tic cancers detected in a population-based screening study, the European randomized study of screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Histopathological prostate cancer characteristics at radical prostatectomy after population based screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening--current controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer—Necessity or nonsense?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Heterogeneity of prostate cancer in radical prostatectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Positive Prostate Biopsy Rate Consistently Increases with Age at the Same Prostate-Specific Antigen Level in Patients with Normal Digital Rectal Examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Staging of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Molecular and cellular biology of the prostate: is it clinically relevant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Tumour-suppressor genes in prostatic oncogenesis: a positional approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Identification of genetic markers for prostatic cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Genomewide scan for prostate cancer-aggressiveness loci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific membrane antigen (PSMA): current benefits and future value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Population-based study of long-term survival in patients with clinically localised prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Screening for prostate cancer. A decision analytic view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Quality-of-life outcomes for men with prostate carcinoma detected by screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer: A challenge for screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening in the Tyrol, Austria: experience and results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Downward trend in prostate cancer mortality in Quebec and Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

PSA screening for prostate cancer: the current controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Attitudes and practices of primary care physicians for prostate cancer screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Attitudes of European urologists to early prostatic carcinoma, II. Attitude to therapy and to screening examinations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Decision aids for patients facing health treatment or screening decisions: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

What questions do patients with curable prostate cancer want answered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The impact of informed consent on patient interest in prostate-specific antigen screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

A randomized controlled trial of shared decision making for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

The Use of Prostate Specific Antigen for Prostate Cancer Screening: A Managed Care Perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

Impact of routine screening for adenocarcinoma of the prostate on stage distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

Systematic sextant biopsies in 651 patients referred for prostate evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900717-3

7 January 2021

inferred from DOI database lookup

Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales

4

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?

31 January 2025

32

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate-specific antigen testing to screen for prostate cancer

31 January 2025

38

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific Antigen

31 January 2025

51

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease

31 January 2025

54

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

31 January 2025

65

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Screening for carcinoma of the prostate with prostate specific antigen

31 January 2025

76

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Systematic Prostatic Biopsies in 100 Men with No Suspicion of Cancer on Digital Rectal Examination

31 January 2025

78

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer

31 January 2025

91

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate cancer: 6. Surgical treatment of localized disease

31 January 2025

146

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate cancer: 7. Radiation therapy for localized disease

31 January 2025

147

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

The economics of prostate cancer screening

31 January 2025

167

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen

31 January 2025

168

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate cancer: 12. The economic burden

31 January 2025

169

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

PSA screening: the bottom line

31 January 2025

180

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

Prostate cancer screening. Why the controversy?

31 January 2025

181

1 reference

https://api.crossref.org/works/10.1016/S0009-8981(01)00717-3

31 January 2025

Identifiers

1 reference

2 August 2017

1 reference